{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:51:49Z","timestamp":1767707509144,"version":"3.33.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ctro.2024.100781","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T03:16:51Z","timestamp":1713669411000},"page":"100781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The first real-world study on the role of carbon ion radiotherapy for oligo-metastatic, persistent, or recurrent (MPR) ovarian\/fallopian tube cancer"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1595-104X","authenticated-orcid":false,"given":"Amelia","family":"Barcellini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3531-9885","authenticated-orcid":false,"given":"Giulia","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Vai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6734-739X","authenticated-orcid":false,"given":"Fabio","family":"Landoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Deborah","family":"Locati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Secondino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Pecorilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-1922","authenticated-orcid":false,"given":"Noriyuki","family":"Okonogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6495-8574","authenticated-orcid":false,"given":"Ester","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2024.100781_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctro.2024.100781_b0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1055\/s-2004-820390","article-title":"First-line therapy in ovarian cancer","volume":"126","author":"du Bois","year":"2004","journal-title":"Zentralbl Gynakol"},{"key":"10.1016\/j.ctro.2024.100781_b0015","doi-asserted-by":"crossref","unstructured":"Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Ann Oncol Off J Eur Soc Med Oncol 2017;28:viii51\u20136. Doi: 10.1093\/annonc\/mdx441.","DOI":"10.1093\/annonc\/mdx441"},{"key":"10.1016\/j.ctro.2024.100781_b0020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/1471-0528.16411","article-title":"PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis","volume":"128","author":"Lin","year":"2021","journal-title":"BJOG"},{"key":"10.1016\/j.ctro.2024.100781_b0025","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/1574892813666180305165256","article-title":"PARP Inhibitors in Ovarian Cancer","volume":"13","author":"Mittica","year":"2018","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.ctro.2024.100781_b0030","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2021.05.018","article-title":"Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review","volume":"162","author":"Alvarez Secord","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.754524","article-title":"Perspectives on PARP Inhibitor Combinations for Ovarian Cancer","volume":"11","author":"Bonadio","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/0300891620966382","article-title":"Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM)","volume":"107","author":"Gadducci","year":"2021","journal-title":"Tumori"},{"key":"10.1016\/j.ctro.2024.100781_b0045","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctro.2024.100781_b0050","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/0284186X.2016.1205218","article-title":"Proton radiotherapy for gynecologic neoplasms","volume":"55","author":"Verma","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0055","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ijgc-2021-002459","article-title":"The role of proton therapy in gynecological radiation oncology","volume":"32","author":"Taunk","year":"2022","journal-title":"Int J Gynecol Cancer off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ctro.2024.100781_b0060","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.2217\/fon-2019-0187","article-title":"Is there a role for carbon therapy in the treatment of gynecological carcinomas? A Systematic Review","volume":"15","author":"Wang","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0065","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/ijgc-2021-002709","article-title":"Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic\/persistent\/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3\/RAD)","volume":"32","author":"Macchia","year":"2022","journal-title":"Int J Gynecol Cancer off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ctro.2024.100781_b0070","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100781_b0075","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100781_b0080","unstructured":"US Department of Health and Human Services National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. n.d."},{"key":"10.1016\/j.ctro.2024.100781_b0085","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1088\/0031-9155\/57\/22\/7543","article-title":"Dose prescription in carbon ion radiotherapy: A planning study to compare NIRS and LEM approaches with a clinically-oriented strategy","volume":"57","author":"Fossati","year":"2012","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ctro.2024.100781_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2022.09.005","article-title":"The role of multiple anatomical scenarios in plan optimization for carbon ion radiotherapy of pancreatic cancer","volume":"176","author":"Molinelli","year":"2022","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.radonc.2021.01.011","article-title":"Robustness of daily dose for each beam angle and accumulated dose for inter-fractional anatomical changes in passive carbon-ion radiotherapy for pancreatic cancer: Bone matching versus tumor matching","volume":"157","author":"Kubota","year":"2021","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.radonc.2014.03.009","article-title":"Conformity and robustness of gated rescanned carbon ion pencil beam scanning of liver tumors at NIRS","volume":"111","author":"Mori","year":"2014","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0105","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/IGC.0000000000001324","article-title":"Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach","volume":"28","author":"Iftode","year":"2018","journal-title":"Int J Gynecol Cancer off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ctro.2024.100781_b0110","doi-asserted-by":"crossref","unstructured":"Barcellini A, Charalampopoulou A, De Cecco L, Fodor A, Rabaiotti E, Candotti G, et al. Ovarian Cancer Radiosensitivity: What Have We Understood So Far? Life (Basel, Switzerland) 2022;13. Doi: 10.3390\/life13010006.","DOI":"10.3390\/life13010006"},{"key":"10.1016\/j.ctro.2024.100781_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12103022","article-title":"Carbon Ion Radiobiology","volume":"12","author":"Tinganelli","year":"2020","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.ctro.2024.100781_b0120","first-page":"12","article-title":"Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease","volume":"37","author":"Willmann","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0125","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2022-003543","article-title":"Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance","author":"Palluzzi","year":"2022","journal-title":"Int J Gynecol Cancer off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ctro.2024.100781_b0130","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1200\/JCO.2022.40.16_suppl.5558","article-title":"OReO\/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis\u2014An exploratory joint analysis of the BRCA and non-BRCA cohorts","volume":"40","author":"Selle","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0135","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0140","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.21873\/anticanres.15681","article-title":"Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study","volume":"42","author":"Gadducci","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctro.2024.100781_b0145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijrobp.2023.04.025","article-title":"Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2\/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mari","volume":"117","author":"Macchia","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100781_b0150","doi-asserted-by":"crossref","unstructured":"Pereira S, Orlandi E, Deneuve S, Barcellini A, Chalaszczyk A, Behm-Ansmant I, et al. The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review. Cancers (Basel) 2022;14. https:\/\/doi.org\/10.3390\/cancers14246252.","DOI":"10.3390\/cancers14246252"},{"key":"10.1016\/j.ctro.2024.100781_b0155","first-page":"5577","article-title":"Clinical Impact of Re-irradiation with Carbon-ion Radiotherapy for Lymph Node Recurrence of Gynecological Cancers","volume":"37","author":"Shiba","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctro.2024.100781_b0160","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","article-title":"A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors","volume":"123","author":"Venkatesulu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctro.2024.100781_b0165","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0360-3016(00)00455-7","article-title":"X-rays vs. carbon-ion tumor therapy: cytogenetic damage in lymphocytes","volume":"47","author":"Durante","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100781_b0170","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctro.2024.100781_b0175","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.dnarep.2013.08.009","article-title":"The complexity of DNA double strand breaks is a critical factor enhancing end-resection","volume":"12","author":"Yajima","year":"2013","journal-title":"DNA Repair (amst)"},{"key":"10.1016\/j.ctro.2024.100781_b0180","doi-asserted-by":"crossref","first-page":"10536","DOI":"10.1074\/jbc.TM117.000375","article-title":"Repair of DNA double-strand breaks by mammalian alternative end-joining pathways","volume":"293","author":"Sallmyr","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctro.2024.100781_b0185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1667\/RR13904.1","article-title":"The major DNA repair pathway after both proton and carbon-ion radiation is NHEJ, but the HR pathway is more relevant in carbon ions","volume":"183","author":"Gerelchuluun","year":"2015","journal-title":"Radiat Res"},{"key":"10.1016\/j.ctro.2024.100781_b0190","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.radonc.2015.08.014","article-title":"Differential DNA repair pathway choice in cancer cells after proton- and photon-irradiation","volume":"116","author":"Fontana","year":"2015","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2013.09.041","article-title":"Deficiency in homologous recombination renders Mammalian cells more sensitive to proton versus photon irradiation","volume":"88","author":"Grosse","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100781_b0200","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ygyno.2018.07.002","article-title":"Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas","volume":"150","author":"Bi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctro.2024.100781_b0205","doi-asserted-by":"crossref","unstructured":"Barcellini A, Loap P, Murata K, Villa R, Kirova Y, Okonogi N, et al. PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? Cancers (Basel) 2021;13. Doi: 10.3390\/cancers13215380.","DOI":"10.3390\/cancers13215380"},{"key":"10.1016\/j.ctro.2024.100781_b0210","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer","volume":"27","author":"de Haan","year":"2021","journal-title":"Clin Cancer Res an off J Am Assoc Cancer Res"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T23:44:59Z","timestamp":1737675899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630824000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":42,"alternative-id":["S2405630824000582"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100781","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The first real-world study on the role of carbon ion radiotherapy for oligo-metastatic, persistent, or recurrent (MPR) ovarian\/fallopian tube cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100781"}}